What is Coherus Oncology, Inc.'s earnings per share (EPS)?

Coherus Oncology, Inc. (CHRS) reported diluted earnings per share of $1.43 for fiscal year 2025. This represents a 472.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Coherus Oncology (CHRS) Financials

CHRS NASDAQ

Trailing 12 months to June 30, 2026

Revenue $50.9M +61.0% YoY

Net Income -$132.1M -173.5% YoY

EPS (Diluted) -$1.06 -123.0% YoY

Operating Cash Flow -$186.0M n/m YoY

Market Cap $156.0M as of Oct 26, 2026

Price / Sales 3.1x on $50.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 2.6x on $60.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CHRS SEC filings page.

Coherus Oncology, Inc. (CHRS) reported $50.9M in revenue over the twelve months to Jun 30, 2026, up 61.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CHRS FY2025 2026-10-25

Coherus still funds a development-heavy cost base, while FY2025 reported profit did not translate into operating cash.

FY2025 net income was $168M, yet operating cash flow was -$139M. With investing cash flow of $375M and an operating loss of $181M, the reported profit appears tied more to non-operating activity than to cash generated by the core operation.

FY2025 R&D was $109M against revenue of $42M, so the business remains organized around development spending rather than a scaled commercial cost base. SG&A was $101M, and the operating loss was $181M; the expense structure therefore overwhelms the gross profit generated.

Liabilities fell 66.0% from FY2024 while assets fell 42.4%, indicating a balance-sheet contraction rather than simple expansion. Equity moved from -$132M to $61M, reversing the prior negative capital position.

Financial Health Signals

Financial Health Score 31/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Coherus Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Coherus Oncology, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 6/100.

Growth

Coherus Oncology, Inc.'s revenue surged 59.8% year-over-year to $42.2M, reflecting rapid business expansion. This strong growth earns a score of 99/100.

Leverage

Liquidity

Coherus Oncology, Inc.'s current ratio of 1.47 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Returns

Coherus Oncology, Inc. generates a 275.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100.

Altman Z-Score Distress

-8.86

Coherus Oncology, Inc. scores -8.86, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.4B against total assets of $258.3M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Coherus Oncology, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

$0.82used

For every $1 of reported earnings, Coherus Oncology, Inc. used $0.82 of operating cash (-$138.5M OCF vs $168.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Coherus Oncology, Inc. reported an operating loss of $181.1M against $9.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$14.3M

YoY+39.5%

QoQ+16.2%

Coherus Oncology, Inc. generated $14.3M in revenue in Q2 2026. This represents an increase of 39.5% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.

EBITDA

-$31.5M

YoYn/m

QoQn/m

Coherus Oncology, Inc.'s EBITDA was -$31.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$20.6M

YoY-106.9%

QoQn/m

Coherus Oncology, Inc. reported a net loss of $20.6M in Q2 2026. This represents a decrease of 106.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.13

YoY-105.1%

QoQn/m

5Y CAGRn/m

10Y CAGRn/m

Coherus Oncology, Inc. earned -$0.13 per diluted share (EPS) in Q2 2026. This represents a decrease of 105.1% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt

$82.9M

YoY-61.8%

QoQ-28.0%

5Y CAGR-24.1%

10Y CAGR-9.3%

Coherus Oncology, Inc. held $82.9M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

155M

YoY+32.9%

QoQ+0.2%

5Y CAGR+15.1%

10Y CAGR+13.5%

Coherus Oncology, Inc. had 155M shares outstanding in Q2 2026. This represents an increase of 32.9% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

70.3%

YoY+3.5pp

QoQ+1.3pp

Coherus Oncology, Inc.'s gross margin was 70.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Return on Equity

-33.9%

YoY-282.4pp

QoQ+14.8pp

Coherus Oncology, Inc.'s quarterly ROE was -33.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 282.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.8 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$21.4M

YoY-18.5%

QoQ-0.5%

Coherus Oncology, Inc. invested $21.4M in research and development in Q2 2026. This represents a decrease of 18.5% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

CHRS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CHRS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY238-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$50.9M	$42.2M+59.8%	$26.4M+2066.6%	$1.2M-99.4%	$211.0M-35.4%	$326.6M-31.4%	$475.8M+33.6%	$356.1Mn/m	$0-100.0%	$1.6M-99.2%	$190.1M+532.8%	$30.0M-3.4%	$31.1M+1030.7%	$2.8M+44.9%	$1.9M
Cost of Revenue	$15.8M	$13.8M+58.3%	$8.7M+1892.5%	$438K-99.4%	$70.1M+21.7%	$57.6M+52.9%	$37.7M+120.6%	$17.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$35.1M	$28.4M+60.6%	$17.7M+2164.4%	$780K-99.4%	$141.0M-47.6%	$269.0M-38.6%	$438.2M+29.3%	$339.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$101.2M	$108.9M+18.6%	$91.8M-4.5%	$96.1M-51.8%	$199.4M-45.1%	$363.1M+154.3%	$142.8M+51.6%	$94.2M-14.6%	$110.2M-32.1%	$162.4M-36.2%	$254.4M+19.4%	$213.1M+172.4%	$78.2M+150.1%	$31.3M-10.3%	$34.9M
SG&A Expenses	$92.6M	$100.6M-19.8%	$125.5M+4.2%	$120.5M-39.3%	$198.5M+17.0%	$169.7M+22.0%	$139.1M+1.5%	$137.0M+45.5%	$94.2M+32.1%	$71.3M+38.2%	$51.6M+43.1%	$36.0M+105.2%	$17.6M+135.3%	$7.5M+35.0%	$5.5M
Operating Income	-$158.7M	-$181.1Mn/m	-$199.7Mn/m	-$215.8Mn/m	-$256.9Mn/m	-$263.9M-268.8%	$156.3M+45.1%	$107.8Mn/m	-$204.4Mn/m	-$232.1Mn/m	-$115.9Mn/m	-$219.1Mn/m	-$64.7Mn/m	-$36.0Mn/m	-$38.5M
EBITDA	N/A	-$179.8Mn/m	-$198.1Mn/m	-$214.0Mn/m	-$253.3Mn/m	-$260.4M-263.5%	$159.2M+43.4%	$111.0Mn/m	-$201.2Mn/m	-$228.7Mn/m	-$112.9Mn/m	-$217.2Mn/m	-$64.0Mn/m	-$35.6Mn/m	-$38.3M
Interest Expense	$9.1M	$9.0M-16.1%	$10.7M-3.1%	$11.1M-65.9%	$32.5M+41.4%	$23.0M+8.5%	$21.2M+20.3%	$17.6M+81.8%	$9.7M+1.4%	$9.6M+19.7%	$8.0M+24081.8%	$33K-99.2%	$3.9M-26.3%	$5.3M+249.6%	$1.5M
Income Tax	N/A	$0n/m	$0n/m	-$380Kn/m	$0n/m	$0-100.0%	$3.5M+17.7%	$2.9Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0	N/A	N/A
Net Income	-$132.1M	$168.0M+489.4%	$28.5Mn/m	-$237.9Mn/m	-$291.8Mn/m	-$287.1M-317.1%	$132.2M+47.2%	$89.8Mn/m	-$209.3Mn/m	-$238.2Mn/m	-$127.3Mn/m	-$223.3Mn/m	-$87.1Mn/m	-$53.6Mn/m	-$33.0M
EPS (Basic)	N/A	$1.43+472.0%	$0.25n/m	-$2.53n/m	-$3.76n/m	-$3.81-305.9%	$1.85+43.4%	$1.29n/m	-$3.22n/m	-$4.48n/m	-$3.04n/m	-$6.01	-$10.64	-$16.10	-$15.85
EPS (Diluted)	-$1.06	$1.43+472.0%	$0.25n/m	-$2.53n/m	-$3.76n/m	-$3.81-335.2%	$1.62+31.7%	$1.23n/m	-$3.22n/m	-$4.48n/m	-$3.04n/m	-$6.01	-$10.64	-$16.10	-$15.85
Diluted Shares (Avg)	N/A	117M+2.3%	115M+21.7%	94M+21.3%	78M+2.9%	75M-9.6%	83M+14.1%	73M+12.5%	65M+22.4%	53M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$14.3M+39.5%	$12.3M+62.0%	$12.7M+64.9%	$11.6M+91.2%	$10.3M-0.4%	$7.6M+229.2%	$7.7M	$6.1M-91.9%
Cost of Revenue	$4.2M+24.9%	$3.8M+43.8%	$4.0M+47.1%	$3.7M+36.4%	$3.4M+87.7%	$2.7M+84.4%	$2.8M	$2.7M-91.7%
Gross Profit	$10.1M+46.7%	$8.5M+71.8%	$8.7M+74.7%	$7.8M+136.2%	$6.9M-19.2%	$4.9M+469.2%	$5.0M	$3.3M-92.1%
R&D Expenses	$21.4M-18.5%	$21.5M-11.5%	$31.0M+49.2%	$27.3M+23.6%	$26.3M+27.7%	$24.4M-14.3%	$20.8M	$22.1M-14.0%
SG&A Expenses	$21.0M-19.5%	$23.1M-11.2%	$23.6M-20.3%	$24.9M-11.4%	$26.0M-5.4%	$26.0M-35.3%	$29.6M	$28.1M-41.7%
Operating Income	-$32.3Mn/m	-$36.2Mn/m	-$45.9Mn/m	-$44.3Mn/m	-$45.5Mn/m	-$45.4Mn/m	-$45.4M	-$46.9Mn/m
EBITDA	-$31.5Mn/m	-$35.3Mn/m	-$45.6Mn/m	-$44.0Mn/m	-$45.2Mn/m	-$45.0Mn/m	-$45.3M	-$46.5Mn/m
Interest Expense	$2.3M+2.0%	$2.2M+1.7%	$2.2M+209.4%	$2.3M-17.8%	$2.3M-43.9%	$2.1M-31.0%	$727K	$2.8M-72.5%
Net Income	-$20.6M-106.9%	-$38.3Mn/m	-$37.6Mn/m	-$35.5Mn/m	$297.8Mn/m	-$56.6M-155.0%	-$50.7M	-$10.8Mn/m
EPS (Basic)	-$0.13-105.1%	-$0.28n/m	-$0.34n/m	-$0.31n/m	$2.57n/m	-$0.49-153.8%	-$0.44n/m	-$0.09n/m
EPS (Diluted)	-$0.13-105.1%	-$0.28-110.9%	-$0.34n/m	-$0.31n/m	$2.57n/m	$2.57+182.4%	-$0.44n/m	-$0.09n/m
Diluted Shares (Avg)	155M+33.4%	136M+17.5%	N/A	116M+0.9%	116M+1.1%	116M+3.0%	N/A	115M+17.9%

Not reported in any period shown, so not listed: Income Tax.

CHRS Balance Sheet

CHRS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY238-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$258.3M-42.4%	$448.5M-28.8%	$629.6M+30.9%	$480.8M-29.2%	$679.3M-19.3%	$841.6M+105.8%	$408.9M+311.1%	$99.5M-38.8%	$162.6M-8.9%	$178.5M-16.0%	$212.4M+13.4%	$187.2M+294.6%	$47.4M	N/A
Current Assets	$206.7M-39.5%	$341.6M-28.2%	$475.6M+24.8%	$381.2M-36.7%	$602.3M-21.5%	$767.5M+123.7%	$343.0M+306.2%	$84.4M-42.0%	$145.5M-9.9%	$161.5M-18.2%	$197.4M+10.2%	$179.1M+292.2%	$45.7M	N/A
Cash & Equivalents	$88.9M-29.5%	$126.0M+22.4%	$102.9M+61.9%	$63.5M-84.8%	$417.2M-22.9%	$541.2M+204.6%	$177.7M+145.5%	$72.4M-43.0%	$126.9M+1.6%	$124.9M-21.0%	$158.2M+5.2%	$150.4M+280.2%	$39.6M+171.9%	$14.5M
Short-Term Investments	$83.2Mn/m	$0-100.0%	$14.9M-88.4%	$128.1Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$3.2M-24.6%	$4.2M+100.9%	$2.1M-94.6%	$38.8M+3.1%	$37.6M-14.9%	$44.2M+351.0%	$9.8M+491.1%	$1.7M	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.9M+19.2%	$1.6M-35.5%	$2.4M+769.4%	$278K	N/A
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	N/A	N/A	$943K0.0%	$943K+4.8%	$900K-4.6%	$943K0.0%	$943K0.0%	$943K0.0%	$943K0.0%	$943K0.0%	$943K0.0%	$943K	N/A	N/A
Total Liabilities	$197.3M-66.0%	$580.5M-29.5%	$823.0M+33.1%	$618.3M+6.3%	$581.6M+3.7%	$560.7M+84.6%	$303.7M+120.0%	$138.1M+4.5%	$132.1M-17.0%	$159.1M-27.4%	$219.3M+82.1%	$120.5M-16.6%	$144.5M	N/A
Current Liabilities	$140.4M-50.4%	$283.0M-14.7%	$331.8M+139.2%	$138.7M-16.1%	$165.3M+13.5%	$145.7M+26.7%	$115.0M+245.7%	$33.3M+17.1%	$28.4M-49.6%	$56.4M-46.8%	$106.0M+104.7%	$51.8M-3.6%	$53.7M	N/A
Non-Current Liabilities	$56.9M-80.9%	$297.5M-39.4%	$491.3M+2.4%	$479.6M+15.2%	$416.3M+0.3%	$415.0M+119.9%	$188.7M+80.1%	$104.8M+1.1%	$103.7M+0.9%	$102.8M-9.3%	$113.3M+65.0%	$68.7M-24.4%	$90.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	$81.4M+1.8%	$79.9M+8.4%	$73.7M	N/A	$76.2M+1.3%	$75.2M	N/A	N/A	N/A	N/A
Total Equity	$61.0Mn/m	-$132.0Mn/m	-$193.4Mn/m	-$137.4M-240.6%	$97.7M-65.2%	$281.0M+167.1%	$105.2Mn/m	-$38.6M-226.4%	$30.5M+48.8%	$20.5Mn/m	-$6.2M-109.3%	$66.8Mn/m	-$97.1M	N/A
Retained Earnings	-$1.4Bn/m	-$1.6Bn/m	-$1.6Bn/m	-$1.3Bn/m	-$1.0Bn/m	-$762.8Mn/m	-$895.0Mn/m	-$984.8Mn/m	-$775.5Mn/m	-$537.3Mn/m	-$410.0Mn/m	-$186.7Mn/m	-$99.6M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$191.2M-56.5%	$266.0M-28.3%	$258.3M-42.4%	$516.5M+2.3%	$439.5M-34.9%	$371.1M-51.4%	$448.5M-28.8%	$505.0M-13.5%
Current Assets	$133.8M-64.8%	$206.0M-33.6%	$206.7M-39.5%	$461.0M+24.9%	$380.2M-31.9%	$310.2M-50.6%	$341.6M-28.2%	$369.0M-17.0%
Cash & Equivalents	$82.9M-61.8%	$115.2M+39.8%	$88.9M-29.5%	$103.4M+5.8%	$216.9M+36.2%	$82.4M-68.3%	$126.0M+22.4%	$97.7M+21.7%
Short-Term Investments	$22.4M+7.9%	$51.8Mn/m	$83.2Mn/m	$88.3Mn/m	$20.7Mn/m	$0n/m	$0-100.0%	$0-100.0%
Inventory	$5.7M+25.6%	$4.8M+37.2%	$3.2M-24.6%	$2.0M-95.7%	$4.5M-92.7%	$3.5M-94.3%	$4.2M+100.9%	$47.6M-28.7%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$130.3M-59.2%	$187.4M-66.2%	$197.3M-66.0%	$428.7M-27.7%	$319.6M-57.9%	$554.5M-34.4%	$580.5M-29.5%	$593.0M-17.3%
Current Liabilities	$75.5M-71.4%	$132.3M-48.1%	$140.4M-50.4%	$372.3M+26.0%	$263.6M-43.1%	$255.0M-52.6%	$283.0M-14.7%	$295.6M+23.3%
Non-Current Liabilities	$54.8M-2.1%	$55.1M-81.6%	$56.9M-80.9%	$56.4M-81.0%	$56.0M-81.1%	$299.5M-2.5%	$297.5M-39.4%	$297.4M-37.7%
Total Equity	$60.8M-49.2%	$78.6Mn/m	$61.0Mn/m	$87.8Mn/m	$119.8Mn/m	-$183.5Mn/m	-$132.0Mn/m	-$88.0Mn/m
Retained Earnings	-$1.4Bn/m	-$1.4Bn/m	-$1.4Bn/m	-$1.3Bn/m	-$1.3Bn/m	-$1.6Bn/m	-$1.6Bn/m	-$1.5Bn/m

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

CHRS Cash Flow Statement

CHRS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY238-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$186.0M	-$138.5Mn/m	-$20.4Mn/m	-$174.9Mn/m	-$241.1Mn/m	-$37.4M-124.3%	$154.1M+443.6%	$28.4Mn/m	-$159.3Mn/m	-$200.3Mn/m	-$252.5Mn/m	-$108.0Mn/m	-$23.9M-255.1%	$15.4Mn/m	-$18.3M
Depreciation & Amortization	N/A	$1.3M-18.8%	$1.6M-11.1%	$1.8M-50.0%	$3.6M+2.9%	$3.5M+21.2%	$2.9M-11.4%	$3.3M+0.7%	$3.2M-4.8%	$3.4M+13.4%	$3.0M+60.3%	$1.9M+177.3%	$674K+66.8%	$404K+82.8%	$221K
Stock-Based Compensation	N/A	$17.0M-39.0%	$27.8M-35.5%	$43.1M-15.0%	$50.7M-1.2%	$51.4M+34.6%	$38.2M+13.6%	$33.6M-3.5%	$34.8M+4.2%	$33.4M+21.8%	$27.4M+64.0%	$16.7M+51.2%	$11.1M+440.9%	$2.0M+361.6%	$443K
Capital Expenditures	N/A	N/A	N/A	$286K-86.0%	$2.0M+58.2%	$1.3M-82.2%	$7.2M+296.9%	$1.8M+130.9%	$789K-82.7%	$4.6M-29.8%	$6.5M+5.7%	$6.2M+116.4%	$2.8M+663.8%	$373K-79.1%	$1.8M
Free Cash Flow	N/A	N/A	N/A	-$175.2Mn/m	-$243.2Mn/m	-$38.7M-126.4%	$146.9M+453.7%	$26.5Mn/m	-$160.1Mn/m	-$204.9Mn/m	-$259.1Mn/m	-$114.2Mn/m	-$26.8M-277.9%	$15.1Mn/m	-$20.0M
Investing Cash Flow	-$9.8M	$375.1M+62.9%	$230.3M+59.2%	$144.6Mn/m	-$166.8Mn/m	-$138.4Mn/m	-$14.4Mn/m	-$12.7Mn/m	-$1.2Mn/m	-$4.4Mn/m	-$6.5M	N/A	N/A	N/A	N/A
Financing Cash Flow	$61.8M	-$273.7Mn/m	-$187.0M-368.6%	$69.6M+28.1%	$54.3M+4.7%	$51.9M-76.8%	$223.9M+150.6%	$89.4M-15.2%	$105.4M-49.0%	$206.8M-8.6%	$226.2M	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$62.1Mn/m	-$57.9Mn/m	-$19.7M-168.9%	-$46.3Mn/m	-$46.6M-178.1%	-$25.8Mn/m	$28.6Mn/m	-$62.0Mn/m
Depreciation & Amortization	$862K+187.3%	$881K+120.2%	$300K+200.0%	$300K-25.0%	$300K-40.0%	$400K-33.3%	$100Kn/m	$400K-50.0%
Stock-Based Compensation	$2.6M-52.4%	$2.4M-55.6%	N/A	$3.4M-50.7%	$5.4M-25.0%	$5.4M-26.6%	N/A	$6.9M-31.0%
Investing Cash Flow	$29.6M-93.6%	$30.7Mn/m	-$2.8Mn/m	-$67.2M-15241.2%	$462.6M+1572.8%	-$17.5M-108.6%	-$542K-101.5%	$444K-99.1%
Financing Cash Flow	$144Kn/m	$53.6Mn/m	$8.1M+3398.3%	$2Kn/m	-$281.5Mn/m	-$264K-129.8%	$231K-36.9%	-$167K-101.5%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

CHRS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CHRS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY238-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	67.2%+0.3pp	66.9%+2.9pp	64.0%-2.8pp	66.8%-15.6pp	82.4%-9.7pp	92.1%-3.1pp	95.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-429.5%	-756.6%	-17716.6%	-121.7%	-80.8%-113.7pp	32.9%+2.6pp	30.3%	N/A	-14918.8%	-61.0%	-729.2%	-207.9%	-1308.4%	-2028.3%
Net Margin	398.4%	108.0%	-19531.4%	-138.2%	-87.9%-115.7pp	27.8%+2.6pp	25.2%	N/A	-15306.6%	-67.0%	-743.2%	-280.1%	-1949.7%	-1738.7%
Return on Equity	275.4%	N/A	N/A	N/A	-293.8%-340.9pp	47.1%-38.3pp	85.4%	N/A	-780.0%-159.6pp	-620.3%	N/A	-130.4%	N/A	N/A
Return on Assets	65.0%+58.7pp	6.4%+44.1pp	-37.8%+22.9pp	-60.7%-18.4pp	-42.3%-58.0pp	15.7%-6.3pp	22.0%+232.4pp	-210.5%-64.0pp	-146.5%-75.1pp	-71.3%+33.8pp	-105.1%-58.6pp	-46.5%+66.5pp	-113.0%	N/A
Current Ratio	1.47+0.3x	1.21-0.2x	1.43-1.3x	2.75-0.9x	3.64-1.6x	5.27+2.3x	2.98+0.4x	2.54-2.6x	5.12+2.3x	2.86+1.0x	1.86-1.6x	3.46+2.6x	0.85	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	0.83+0.5x	0.28-0.4x	0.70	N/A	2.50-1.2x	3.66	N/A	N/A	N/A	N/A
Liabilities-to-Equity	3.23	N/A	N/A	N/A	5.95+4.0x	2.00-0.9x	2.89	N/A	4.33-3.4x	7.75	N/A	1.80	N/A	N/A
Asset Turnover	0.16+0.1x	0.06+0.1x	0.00-0.4x	0.440.0x	0.48-0.1x	0.57-0.3x	0.87+0.9x	0.000.0x	0.01-1.1x	1.07+0.9x	0.140.0x	0.17+0.1x	0.06	N/A
FCF Margin	N/A	N/A	-14381.8%	-115.2%	-11.9%-42.7pp	30.9%+23.4pp	7.4%	N/A	-13165.7%	-136.3%	-380.0%	-86.1%	547.1%	-1055.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	70.3%+3.5pp	69.0%+3.9pp	68.3%+3.8pp	67.8%+12.9pp	66.9%-15.5pp	65.1%+27.4pp	64.4%	54.9%-1.2pp
Operating Margin	-226.0%	-293.7%	-359.9%	-383.1%	-443.6%	-597.9%	-586.9%	-774.2%
Net Margin	-144.2%	-311.4%	-295.3%	-307.1%	2903.9%	-744.4%	-655.6%	-177.6%
Return on Equity	-33.9%-282.4pp	-48.8%	-61.7%	-40.5%	248.5%	N/A	N/A	N/A
Return on Assets	-10.8%-78.5pp	-14.4%+0.8pp	-14.6%-3.3pp	-6.9%-4.8pp	67.8%+69.7pp	-15.2%-28.7pp	-11.3%	-2.1%+4.7pp
Current Ratio	1.77+0.3x	1.56+0.3x	1.47+0.3x	1.240.0x	1.44+0.2x	1.22+0.1x	1.21-0.2x	1.25-0.6x
Liabilities-to-Equity	2.14-0.5x	2.38	3.23	4.88	2.67	N/A	N/A	N/A
Asset Turnover	0.07+0.1x	0.050.0x	0.050.0x	0.020.0x	0.020.0x	0.020.0x	0.02	0.01-0.1x

Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Coherus Oncology, Inc. CHRS	FY2025	$42.2M	$168.0M	N/A	$156.0M	31/100
Instil Bio, Inc. TIL	FY2025	N/A	-$71.4M	N/A	$39.6M	—
Greenwich LifeSciences, Inc. GLSI	FY2025	N/A	-$19.4M	N/A	$235.3M	—
Agenus Inc. AGEN	FY2025	$114.2M	$115K	0.1%	$285.9M	17/100
Seres Therapeutics, Inc. MCRB	FY2025	$789K	$5.7M	N/A	$21.0M	—

Where Coherus Oncology, Inc. Ranks

Frequently Asked Questions

What is Coherus Oncology, Inc.'s annual revenue?

Coherus Oncology, Inc. (CHRS) reported $42.2M in total revenue for fiscal year 2025. This represents a 59.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Coherus Oncology, Inc.'s revenue growing?

Coherus Oncology, Inc. (CHRS) revenue grew by 59.8% year-over-year, from $26.4M to $42.2M in fiscal year 2025.

Is Coherus Oncology, Inc. profitable?

No, Coherus Oncology, Inc. (CHRS) reported a net loss of $132.1M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $168.0M.

What is Coherus Oncology, Inc.'s EBITDA?

Coherus Oncology, Inc. (CHRS) had EBITDA of -$179.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Coherus Oncology, Inc.'s gross margin?

Coherus Oncology, Inc. (CHRS) had a gross margin of 67.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Coherus Oncology, Inc.'s return on equity (ROE)?

Coherus Oncology, Inc. (CHRS) has a return on equity of 275.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Coherus Oncology, Inc.'s operating cash flow?

Coherus Oncology, Inc. (CHRS) recorded an outflow of $138.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Coherus Oncology, Inc.'s total assets?

Coherus Oncology, Inc. (CHRS) had $258.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Coherus Oncology, Inc. spend on research and development?

Coherus Oncology, Inc. (CHRS) invested $108.9M in research and development during fiscal year 2025.

How many shares does Coherus Oncology, Inc. have outstanding?

Coherus Oncology, Inc. (CHRS) had 150M shares outstanding as of fiscal year 2025.

What is Coherus Oncology, Inc.'s current ratio?

Coherus Oncology, Inc. (CHRS) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.

What is Coherus Oncology, Inc.'s liabilities-to-equity ratio?

Coherus Oncology, Inc. (CHRS) had a liabilities-to-equity ratio of 3.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is Coherus Oncology, Inc.'s return on assets (ROA)?

Coherus Oncology, Inc. (CHRS) had a return on assets of 65.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Coherus Oncology, Inc.'s P/E ratio?

Coherus Oncology, Inc. (CHRS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $156.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Coherus Oncology, Inc.'s price-to-sales ratio?

Coherus Oncology, Inc. (CHRS) trades at 3.1x sales, its market capitalization divided by $50.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $156.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Coherus Oncology, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Coherus Oncology, Inc. (CHRS) held $172.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $138.5M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Coherus Oncology, Inc.'s Altman Z-Score?

Coherus Oncology, Inc. (CHRS) has an Altman Z-Score of -8.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Coherus Oncology, Inc.'s Piotroski F-Score?

Coherus Oncology, Inc. (CHRS) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Coherus Oncology, Inc.'s earnings high quality?

For every $1 of reported earnings, Coherus Oncology, Inc. (CHRS) used $0.82 of operating cash (-$138.5M OCF vs $168.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Coherus Oncology, Inc. cover its interest payments?

Coherus Oncology, Inc. (CHRS) reported an operating loss of $181.1M against $9.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Coherus Oncology, Inc.?

Coherus Oncology, Inc. (CHRS) scores 31 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.